FDA’s estimates of the cost of the drug development tool qualification provisions in the 21st Century Cures bill suggest it is potentially ripe for a user fee.
Biomarker qualification package reviews could require resources similar to a review of a drug application with clinical data – about...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?